Journal: Brain Pathology

Article Title: New clinicopathological associations and histoprognostic markers in ILAE types of hippocampal sclerosis

doi: 10.1111/bpa.12596

Figure Lengend Snippet: CD34+ cells are associated with rarer patterns of hippocampal sclerosis. A–D, I–J. A CD34+ nodular case. CD34 immunopositive/CD34+ stellate cells formed a nodule (solid arrowheads in (A‐B). Nestin immunolabeling showed a frequent extravascular stellate pattern in the area of the CD34+ nodule (solid arrowhead in C) whereas Vimentin immunolabeling showed no extravascular immunolabeling (D). E–H, K–L. A CD34+ scarce case. E. An isolated CD34+ extravascular stellate cell is observed (open arrowheads in E, F). Nestin immunolabeling showed a scant stellate extravascular pattern in the area of the CD34+ stellate cell (open arrowhead in G) whereas Vimentin immunolabeling showed no extravascular immunolabeling (H). Double immunolabelings showed the co‐expression in stellate cells of Nestin (brown) and CD34 (red) (I), and SOX2 (pink) and CD34 (brown) (J) in a CD34+ nodular case. Double immunolabelings showed the co‐expression in stellate cells of Nestin (brown) and CD34 (red) (K, higher magnification in insert), and of SOX2 (pink) and CD34 (brown) (L) in a CD34+ scarce case. M–P. Distribution of CD34 immunolabeling (CD34 negative in black, CD34+ scarce in orange and CD34+ nodular in green) for type 1 (M), type 2 (N), type 3 (O), the pattern noHS (P). Q–S. A CD34+ nodular case with BRAF V600E immunopositive neurons. Q. A moderate immunolabeling of scarce cells by P53 (solid arrowheads). The BRAF V600E immunolabeling is positive in neurons (solid arrowheads in r,s). T. A CD34+ scarce case with BRAF V600E+ neurons (open arrowhead). Scale bars: (A,E) 400 μm; (B–D,F–H) 100 μm; (I–L,T) 50μm; (Q,R) 200μm; (S) 20μm.

Article Snippet: Primary antibodies were as follows: BRAF V600E (mouse monoclonal VE1, 1:100, Abcys Eurobio), CD31 (monoclonal mouse JC70A, 1:30, Dako) CD34 (monoclonal mouse QBEnd10, 1:50, Dako), ELAVL2 (rabbit polyclonal, 1:500, Proteintech), GFAP (monoclonal mouse 6F2, 1:500, Dako), Internexin alpha/INA (monoclonal mouse 2E3, 1:100, Quartett Biochemicals), Nestin (monoclonal mouse 10C2, 1:2000, Sigma‐Aldrich), NeuN (Monoclonal mouse MAB377, 1:100; Merck Millipore), OLIG2 (rabbit monoclonal EP112, 1:200, Epitomics), P53 (monoclonal mouse, DO‐7, 1:100 Dako), SOX2 (rabbit monoclonal SP76, 1:300, Sigma‐Aldrich), Vimentin (monoclonal mouse V9, 1:50 Dako).

Techniques: Immunolabeling, Isolation, Expressing

Journal: Brain Pathology

Article Title: New clinicopathological associations and histoprognostic markers in ILAE types of hippocampal sclerosis

doi: 10.1111/bpa.12596

Figure Lengend Snippet: Classification of CD34+ hippocampal sclerosis according to BRAF V600E and INA status. A,C,E,G–I. A case of “BRAF V600E+ HS” with BRAF V600E positive neurons. B,D,F,J–L. A case of hippocampal MVNT. A,B. CD34 immunolabeling showed a nodular pattern of CD34 positive stellate cells (solid arrowheads). C,D. NeuN immunolabeling showed a neuronal loss that is predominant in CA4 (solid arrowheads) corresponding to HS ILAE type 3. E. Absence of INA positive abnormal neurons. F. Presence of numerous abnormal INA+ neurons (solid arrowheads). G–I. Absence of abnormal neurons according to NeuN, ELAVL2 and INA immunolabelings in the white matter of CA2 (open arrowheads) in a BRAF V600E+ HS. J–L. Presence of Neun Negative, ELAVL2 positive, INA positive abnormal neurons (solid arrowheads) in the white matter of CA2 in a MVNT. Scale bars: (A–F) 2.5 mm; (G–L) 200 μm. Abbreviations: INA = internexin alpha; MVNT = multinodular and vacuolating neuronal tumor.

Article Snippet: Primary antibodies were as follows: BRAF V600E (mouse monoclonal VE1, 1:100, Abcys Eurobio), CD31 (monoclonal mouse JC70A, 1:30, Dako) CD34 (monoclonal mouse QBEnd10, 1:50, Dako), ELAVL2 (rabbit polyclonal, 1:500, Proteintech), GFAP (monoclonal mouse 6F2, 1:500, Dako), Internexin alpha/INA (monoclonal mouse 2E3, 1:100, Quartett Biochemicals), Nestin (monoclonal mouse 10C2, 1:2000, Sigma‐Aldrich), NeuN (Monoclonal mouse MAB377, 1:100; Merck Millipore), OLIG2 (rabbit monoclonal EP112, 1:200, Epitomics), P53 (monoclonal mouse, DO‐7, 1:100 Dako), SOX2 (rabbit monoclonal SP76, 1:300, Sigma‐Aldrich), Vimentin (monoclonal mouse V9, 1:50 Dako).

Techniques: Immunolabeling

Journal: Brain Pathology

Article Title: New clinicopathological associations and histoprognostic markers in ILAE types of hippocampal sclerosis

doi: 10.1111/bpa.12596

Figure Lengend Snippet: Radiological features of BRAF V600E+ hippocampal sclerosis and hippocampal MVNT. A‐B. BRAF V600E+ hippocampal sclerosis. Coronal T2 sequence showing discrete atrophy, loss of digitation and T2 hyperintensity of the right hippocampus (vertical arrows). C–E. Hippocampal MVNT. Coronal T2 (C), FLAIR (D) and T1 (E) sequences show discrete atrophy of left internal temporal structures (vertical arrows), associated with extensive T2 and FLAIR hyperintensities involving the hippocampus, parahippocampal gyrus, fusiform gyrus and part of the inferior temporal gyrus (oblique arrows). A pseudocyst (arrowheads) is visible within the fusiform gyrus, hyperintense on T2 and hypointense on T1 and FLAIR images.

Article Snippet: Primary antibodies were as follows: BRAF V600E (mouse monoclonal VE1, 1:100, Abcys Eurobio), CD31 (monoclonal mouse JC70A, 1:30, Dako) CD34 (monoclonal mouse QBEnd10, 1:50, Dako), ELAVL2 (rabbit polyclonal, 1:500, Proteintech), GFAP (monoclonal mouse 6F2, 1:500, Dako), Internexin alpha/INA (monoclonal mouse 2E3, 1:100, Quartett Biochemicals), Nestin (monoclonal mouse 10C2, 1:2000, Sigma‐Aldrich), NeuN (Monoclonal mouse MAB377, 1:100; Merck Millipore), OLIG2 (rabbit monoclonal EP112, 1:200, Epitomics), P53 (monoclonal mouse, DO‐7, 1:100 Dako), SOX2 (rabbit monoclonal SP76, 1:300, Sigma‐Aldrich), Vimentin (monoclonal mouse V9, 1:50 Dako).

Techniques: Sequencing

Journal: iScience

Article Title: RIPOR2 promotes multinucleation of melanoma cells downstream of the RAS/ERK oncogenic pathway

doi: 10.1016/j.isci.2026.115734

Figure Lengend Snippet: RIPOR2 is expressed in the melanocytes of an intermediate-grade melanocytic lesion Adjacent sections of an early BRAF V600E -positive intraepidermal melanoma. Dotted boxes are magnified in the adjacent images. (A) H&E stain shows tissue disorganization in the center of the section. (B) Immunohistochemistry with an anti-BRAF V600E antibody stains the mutated melanocytes and highlights the malignant lesion zone. (C) Immunofluorescence with antiSOX10. (D) Anti-RIPOR2 antibodies demonstrated that RIPOR2 is expressed in SOX10+ epidermal nests of BRAF V600E -positive melanocytes, suggesting that it is expressed in malignant melanocytes. The RIPOR2 staining is cytoplasmic. Blue corresponds to Hoechst nuclear staining in all panels. Scale bars, 100 μm.

Article Snippet: 3.5 μm thick paraffine sections were done from samples and staining was done on a Benchmark ULTRA immunohistochemistry automated system (Ventana, Roche Diagnostics), using the anti-BRAF antibody directed against the V600E mutant form (clone VE1, Eurobio Scientific), dilution 1:250, Optiview DAB detection (Ventana).

Techniques: Staining, Immunohistochemistry, Immunofluorescence

Journal: Frontiers in Neurology

Article Title: Neuroplasticity Mechanisms in Frontal Brain Gliomas: A Preliminary Study

doi: 10.3389/fneur.2022.867048

Figure Lengend Snippet: Demographic and clinical features of patients with frontal intra-axial tumor.

Article Snippet: Immunohistochemistry was performed in an automated stainer (Ventana, Tucson, AZ, using Ventana purchased pre-diluted antibodies): antibodies anti-GFAP (clone EP672Y, Cell-Marquez), anti-Olig2 (clone EP112, Cell-Marquez), anti- synaptophysin (clone MRQ-40, Cell-Marquez), anti-BRAF V600E (clone VE1, Roche), anti-CD34 (clone QBEnd/10, Roche), anti-IDH1 R132H (Clone H09, Dianova), anti-ATRX (polyclonal, Sigma), anti-p53 (clone DO-7, Roche) were used.

Techniques: Histopathology, Methylation

Journal: Cancer Cell International

Article Title: TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response

doi: 10.1186/s12935-019-0768-3

Figure Lengend Snippet: WM35-R was selected from WM35 for resistance to MDM2 inhibitors. a Growth inhibition curves for the response of WM35 and WM35-R cells to treatment with MDM2 inhibitors for 72 h. Immunobloting of WM35 and WM35-R following treatment with MDM2 inhibitors, RG7388 ( b ) and HDM201 ( c ) for 6 h. d CDKN1A , MDM2 , PUMA and BAX expressions by qRT-PCR in WM35 and WM35-R following treatment with 0.2 µM RG7388 for 6 and 24 h. e Chromatogram showing p53 mutations in WM35-R. f Mutation specific PCR detecting the presence of a low frequency of mutant alleles in the parental WM35 cell population

Article Snippet: Primary antibodies against p53 (DO-7) (#M7001, Dako), MDM2 (Ab-1) (#OP46, Merck Millipore), p21 WAF1 (EA10) (#OP64, Calbiochem), p-ERK (E-4) (sc-7383, Santa Cruz), ERK (K-23) (sc-94, Santa Cruz), GAPDH (14C10) (#2118, Cell Signaling Technology), BRAF V600E (VE1, Spring Bioscience), Actin (A4700, Sigma) and secondary goat anti-mouse/rabbit horseradish peroxidase-conjugated antibodies (#P0447/P0448, Dako) were used.

Techniques: Inhibition, Western Blot, Quantitative RT-PCR, Mutagenesis

Journal: Cancer Cell International

Article Title: TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response

doi: 10.1186/s12935-019-0768-3

Figure Lengend Snippet: SN40R2 selected from SJSA-1 was resistant to MDM2 inhibitors and retained an NRAS mutation. a Growth inhibition curves of SJSA-1 and SN40R2 treated with MDM2 inhibitors for 72 h. b , c Immunobloting of SJSA-1 and SN40R2 treated with MDM2 inhibitors, RG7388 ( a ) and HDM201 ( c ) for 6 h. d CDKN1A , MDM2 , BBC3 ( PUMA ) and BAX expressions by qRT-PCR in SJSA-1 and SN40R2 treated with HDM201 for 6 h. e Chromatogram showing a c.181C>A NRAS mutation in both SJSA-1 and SN40R2

Article Snippet: Primary antibodies against p53 (DO-7) (#M7001, Dako), MDM2 (Ab-1) (#OP46, Merck Millipore), p21 WAF1 (EA10) (#OP64, Calbiochem), p-ERK (E-4) (sc-7383, Santa Cruz), ERK (K-23) (sc-94, Santa Cruz), GAPDH (14C10) (#2118, Cell Signaling Technology), BRAF V600E (VE1, Spring Bioscience), Actin (A4700, Sigma) and secondary goat anti-mouse/rabbit horseradish peroxidase-conjugated antibodies (#P0447/P0448, Dako) were used.

Techniques: Mutagenesis, Inhibition, Western Blot, Quantitative RT-PCR

Journal: Cancer Cell International

Article Title: TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response

doi: 10.1186/s12935-019-0768-3

Figure Lengend Snippet: Proposed model for MAPK inhibition in paired TP53 WT and TP53 MUT cell lines selected for resistance to MDM2 inhibitors. WM35-R ( a ) and SN40R2 ( b ) were selected from WM35 and SJSA-1 respectively and both were sensitive to growth inhibition by MAPK pathway inhibition. The TP53 MUT cells lost p53-dependent apoptosis but retained p53-independent cell cycle arrest and growth inhibition in response to inhibition of the MAPK pathway. SJSA-1 showed minimal p53-dependent apoptosis in response to MAPK pathway inhibition, plausibly resulting from p53 suppression by overexpression of MDM2

Article Snippet: Primary antibodies against p53 (DO-7) (#M7001, Dako), MDM2 (Ab-1) (#OP46, Merck Millipore), p21 WAF1 (EA10) (#OP64, Calbiochem), p-ERK (E-4) (sc-7383, Santa Cruz), ERK (K-23) (sc-94, Santa Cruz), GAPDH (14C10) (#2118, Cell Signaling Technology), BRAF V600E (VE1, Spring Bioscience), Actin (A4700, Sigma) and secondary goat anti-mouse/rabbit horseradish peroxidase-conjugated antibodies (#P0447/P0448, Dako) were used.

Techniques: Inhibition, Over Expression